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Abstract: Aim: To summarize the main findings on variable cardiovascular risk factors and their 
management in everyday practice. 
Methods: A narrative review of the relevant literature known to the authors and incorporation of 
healthy changes tips in defined variable cardiovascular risk factors. 
Results: There are known variable cardiovascular risk factors to be claimed as those that should be 
changed in order to achieve a better prevention of cardiovascular disease development. But, most 
papers are informative and they didn’t incorporate exact measures for each variable risk factor. Our 
paper shows exact measures for each variable cardiovascular risk factor that should be incorporate 
in everyday practice of family practitioners and cardiologists as well. 
Conclusion: The best cardiovascular disease’ prevention should include a multidisciplinary team of 
experts and the entire community with the support of governmental and non-governmental organi-
zations that will contribute to improving the lifestyle of individuals and the entire community 
through their activities and legal provisions. The most important factors in cardiovascular disease 
management are: recognizing individual risk factors, monitoring them, and assisting in changes in 
life-style habits that directly affect the defined risk factors of a patient. The simplest and most prac-
ticable guidelines for CV prevention in accordance with the national, cultural and socioeconomic 
aspects of their country of work are needed. 
Keywords: Mortality and morbidity, Cardiovascular Diseases (CVDs), dyslipidemia, obesity, smoking, sedentary lifestyle, 
arterial hypertension, diabetes mellitus. 
1. INTRODUCTION 
 Cardiovascular Diseases (CVD) are heart and circulatory 
system disorders. It is a set of heterogeneous diseases whose 
underlying cause of development is most often atherosclero-
sis [1, 2]. CVD are chronic diseases that are gradually evolv-
ing throughout life, and are asymptomatic for a long time. 
Usually only the advanced disease causes symptoms or the 
first symptom can be sudden death [3]. For years they have 
been the leading cause of premature mortality across the 
world. It is estimated that by the year 2030, 23.6 million 
people will die of CVD per year. There is a mild tendency to 
decrease mortality and incidence of CVD in north western 
and southern Europe [2]. 
 CVD causes 49% of mortality in Europe, which is the 
most important cause of premature mortality and Disability 
Adjusted Life Years ("DALYS") in Europe, thus creating a 
great public health importance on this topic. Approximately 
€ 192 billion is the cost of annual health care for CVD in the 
European Union [4]. 
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 CVD are caused by multiple factors. Some of them are 
invariable (age, gender, genetic heritage), others are variable, 
that is, they can be affected (smoking tobacco, physical inac-
tivity, poor eating habits, elevated blood pressure, type 2 
diabetes, dyslipidemia, obesity) [4]. 
 For the reduction of the CVD mortality rate in highly 
developed countries, controlling risk factors (45-75%) and 
proper CVD treatment (25-55%) are responsible [5-7]. 
 This review aims to summarize the available information 
on measurable variable CVD risk factors through existing 
literature and integrate them with healthy tips that can be 
managed in everyday practice. 
2. PREVENTION OF CARDIOVASCULAR DISEASES 
 Prevention of CVD is defined as a coordinated pool of 
activity at the population level or individual level with the 
aim of eliminating or reducing to the lowest level of CVD 
incidence and their consequences [8]. 
 The report of the Expert Committee for the Prevention of 
the CVD and WHO established in 1982 measures of preven-
tion that need to have 3 components of the strategy [9]: 
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1. Population strategy - Lifestyle habits and environ-
mental factors, socioeconomic determinants that may 
cause CVD development, affect these activities at the 
level of the entire population [8, 10]. 
2. High-risk strategy - Identification of high risk indi-
viduals and measures that will reduce their risk fac-
tors. 
3. Secondary prevention - Prevention of the occurrence 
or reoccurrence and progression of disease in patients 
with already proven CVD. 
 High-risk and secondary strategies are directed at indi-
viduals and must be an integral part of our clinical practice 
[9]. The population strategy is focused on the entire commu-
nity, and is an integral part of food, transport, employment, 
education and health policies and other policies at the level 
of Europe, the state, the region and the local community. 
Population and clinical approach should be complementary, 
but the population strategy is the basis for reducing the inci-
dence of CVD in Europe. It focuses on social and economic 
determinants of illness through political activities. It tends to 
change the lifestyle habits: reducing the number of smokers, 
increasing physical activity, promoting healthy living habits. 
Investment and political will are needed to achieve these 
goals [8-11].  
 According to the latest guidelines of the European Cardi-
ology Society (ESC) CVD prevention, the focus is on the 
population approach to prevention, on disease-specific inter-
ventions, female population, younger individuals and ethnic 
minorities. The emphasis is on the whole life cycle of CVD 
prevention [12] (Figs. 1 and 2 and Table 1). 
3. MONITORING MEASURABLE CHANGES OF 
FACTORS IMPORTANT FOR CARDIOVASCULAR 
DISEASES DEVELOPMENT 
 CVD prevention measures must be an integral part of 
everyday medical work to achieve optimal results. It is there-
fore important to define CVD prevention priorities. CVD 
prevention guidelines provide the procedures for defining the 
preventive measures to be taken, taking into account the 
health policies of individual countries and the incidence of 
CVD in individual countries in order to achieve unambigu-
ous access to patients. 
 It is most important to have a consistent approach with 
defined monitoring parameters based on which an individ-
ual's risk assessment will be carried out. The risk assessment 
is one of the most important measures that define all future 
treatments of patients.  
 Reduction of CVD morbidity and mortality is the goal 
of clinical and population preventative strategies. Since 
CVD are multifactorial, it is necessary to monitor and act 
upon several different risk factors at the same time. Health 
professionals use the algorithm according to ESC guide-
lines in their work on CVD prevention. The first ESC pre-
vention guidelines were published in 1994 and since then 
they have been revised several times. The last are published 
2016. 
 
 At the same time, the existence of multiple risk factors 
multiplies the risk of CVD, and the risk of myocardial in-
farction progressively increases [13-17]. Therefore, the esti-
mate of the CVD risk is of the most importance in the opti-
mal management of prevention and treatment [18]. 
 Stratification of CVD risk is important because there 
are people who do not yet have manifest atherosclerotic 
disease but can develop CVD [12]. Total CVD risk means 
that an individual is likely to develop a fatal cardiovascu-
lar event for a certain period of time. It is important for 
the physician to be able to assess the risk quickly and to 
make a quick decision on further treatment (evidence-
based management). To help diagnose and monitor indi-
viduals who have increased risk for developing CVD, 
there are developed monitoring models that are being 
used today in Europe in the form of Systemic Coronary 
Risk Estimation (SCORE) tables (Figs. 1 and 2). SCORE 
tables are used only for people without known CVD. Peo-
ple with already manifest atherosclerotic vascular disease 
are in the group of high CVD risk and as such should be 
treated [19]. 
 Recommendations for using the SCORE table [8, 13]: 
- For apparently healthy adults (>40g.) without signs of 
CVD, Diabetes Mellitus (DM), chronic kidney dis-
ease, familial hypercholesterolemia, because these 
patients are already high risk and are therefore the 
priority for intensive counseling on risk factors. 
- Evaluate for each individual the total ten-year risk of 
death by sex, smoking, age, systolic blood pressure 
and total cholesterol. 
- Low risk individuals should be advised to maintain 
such status, and those with an estimated risk >5% 
should dedicate particular attention to reduce it. 
- Define the relative risk for people under the age of 40. 
- The effect of cholesterol, smoking status and systolic 
pressure can be estimated from the table. 
 The decision on treatment strategy depends on the initial 
risk level. Categorization into different groups of total CVD 
risks is agreed but is recommended for its simplicity [4]. The 
total CVD risk may be higher than that shown in the tables 
under the following circumstances: 
- If an individual moves to an older age group. 
- In asymptomatic patients with signs of atherosclerotic 
disease (computer tomography, ultrasound). 
- In individuals with significant positive family history 
of early cardiovascular deaths. 
- In individuals with low high density lipoproteins 
(HDL) cholesterol, high triglycerides, glucose intoler-
ance, elevated C-Reactive Protein (CRP), elevated fi-
brinogen, elevated homocysteine, elevated apolipo-
protein B (APOB), elevated lipoproteins, and obese 
people with the sedentary lifestyle [8]. 
 Separate tables are compiled for the high and low risk 
countries of Europe of high and low risk, and in the future 
for each country will be able to define individualized risk 
tables. 
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Fig. (1). SCORE chart: 10-year risk of fatal cardiovascular disease 
(CVD) in countries of high CVD risk. 
Source: 2016 European Guidelines on cardiovascular disease pre-





Fig. (2). SCORE chart: 10-year risk of fatal cardiovascular disease 
(CVD) in countries of low CVD risk. 
Source: 2016 European Guidelines on cardiovascular disease pre-




 The benefits of estimating total CVD risk and treating 
accordingly are 2-fold [20]. The first is the direction of pre-
ventive efforts toward those who will be most likely to bene-
fit. The second is the reassurance and avoidance of side ef-
fects in lower-risk persons who will derive less benefit [20]. 
In the most people, CVD is the product of more than 1 risk 
factors. A combination of several factors result in much 
higher total risk [20]. Therefore, SCORE system help to es-
timate total risk. For young person, we use relative risk esti-
mation (they can be at low absolute but high relative risk) 
[20]. We must encourage risk evaluation and management 
because it improves the primary prevention of CVD. 
4. VARIABLE RISK FACTORS OF CARDIOVASCU-
LAR DISEASES 
 Factors contributing to the development of atherosclero-
sis and CVD are called CVD risk factors. Their action is 
multiplied thus presenting a big public health problem. CVD 
risk factors may be variable and invariable. 
 Invariable risk factors are those we cannot influence (age 
and gender, men over age 45 and women over 55 years re-
spectively in menopause, inheritance-positive family his-
tory). 
 Variable risk factors are those we can influence by 
changing bad habits. Variable risk factors include: smoking, 
inadequate physical activity, elevated blood pressure, in-
creased body weight (obesity), increased levels of fat in the 
blood (cholesterol, triglyceride), DM. 
 The goal of managing the variable risk factors is to re-
duce CVD morbidity and mortality. Clinical studies: 
Framingham, Multiple Risk Factor Intervention Trial 
(MRFIT) [21], Asia Pacific Cohort Studies Collaboration 
(APCSC) [22], INTERHEART [23] has shown that multiple 
risk factors multiply CVD risk and the risk of myocardial 
infarction progressively increases. Thus, CVD are multifac-
torial diseases, and these have to be monitored at several 
levels and in particular, an important estimate of variable 
risk factors is in diagnosis, monitoring and treatment [24]. 
 The influence of variable risk factors at the risk of myo-
cardial infarction has been demonstrated in the major inter-
national clinical study INTERHEART, which included 52 
countries and the results of which were published in 2004. It 
has proven the importance of preventive measures to reduce 
the incidence of myocardial infarction [25]. According to the 
European Society of Cardiology (ESC) Guidelines, recom-
mendations are given for managing variable CVD risk fac-
tors in the way presented below. 
4.1. Smoking 
 Smoking cigarettes is a dominant risk factor for cardio-
vascular and non-cardiovascular mortality and morbidity. It 
is estimated that by the year 2025, there will be 1.6 billion 
smokers in the world, and that 10 million people a year will 
die for smoking [10]. Unfortunately, there is still a rise in 
smokers among women and adolescents in Europe [12, 26]. 
The ten-year risk of fatal cardiovascular events is doubled in 
smokers [12]. Passive smoking increases the risk of CVD [8, 
12, 27]. 
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 Smoking is one of the preventable risk factors with the 
greatest contribution in the development of CVD and as such 
must be the most important factor that the physician tends to 
reduce.  
 There are a number of measures we can use to help the 
patient and our recommendations range from individual ap-
proaches through group therapies to medication approaches: 
1. Self-help technique. 
2. Individual advisory. 
3. Group therapy. 
4. Substitution therapy with nicotine. 
5. Antidepressants (smoking cessation and nicotine up-
set can provoke depression). 
6. Family support and spouse. 
 Promoting non-smoking includes social programs as part 
of health promotion activities. Many European countries 
have declared a "smoke-free" zone (ban on smoking at the 
workplace, in public institutions, restaurants ...), which is 
very important in stimulating individual efforts to stop smok-
ing [9]. The goal is to reach Europe as a smoking-free 
Europe by 2030 [8]. Public health measures and legislation 
are also important: smoking ban, tobacco tax, media cam-
paigns ... High taxes on all tobacco products have been 
shown to be an effective measure to reduce youth smoking 
[8]. Children in schools should be taught with healthy life-
style habits, including noxiousness smoking lectures, en-
couraging young people not to start smoking or to stop 
smoking [8]. 
4.2. Physical (in) Activity 
 Physical inactivity is a risk factor of CVD development, 
but also the development of a number of other chronic dis-
eases. Even 60% of the world's population does not meet the 
minimum recommended 30 minutes daily of moderate 
physical activity. The CVD risk is increased by 1.5 times in 
people living a sedentary lifestyle. Physical inactivity causes 
2 million deaths per year and 22% of all ischemic heart dis-
ease [28]. Due to the increased physical inactivity of young 
people, a higher increase in CVD is expected. 
 Regular physical activity is protective and has many 
benefits: it directly affects the reduction of already existing 
vascular lesions and reduces other risk factors (reduces body 
weight, reduces lipid levels, blood sugar, reduces arterial 
pressure) and thus decreases the incidence of coronary dis-
ease [8, 9]. 
 It reduces the progression of atherosclerosis, protects the 
patient from oxidative stress, increases insulin sensitivity, 
decreases the incidence of malignant arrhythmias, balances 
the vegetative system [9, 29-31]. Consequently reduces total 
and CV mortality. 
 Promoting physical activity should start already in child-
hood. In all age groups, physical activity is an important part 
of preventative CVD measures. 
 Cardiovascular patients, especially after acute coronary 
syndrome, intervention on the coronary arteries or heart sur-
gery, should undergo a CVD rehabilitation program during 
which they will be monitored, and tested using treadmill 
bicycle exercise with Electrocardiography (ECG) and blood 
pressure monitoring. The patient should monitor his fre-
quency on the pulse monitor while exercising at home. 
Coronary patients with low clinical risk should moderately 
or intensively exercise 30 minutes 3 to 5 times a week. 
Coronary patients with moderate to high clinical risk should 
strictly individually adjust the exercise program. Even the 
heaviest patients have benefit from low intensity exercise, 
but under the supervision of experts. Exercising encourages 
their self-reliance and reduces depression [8]. 
 Regular exercise is important in primary and secondary 
CVD prevention. Before starting the exercise, to determine 
the intensity of the exercise, it is important to stratify the CV 
risk to prevent possible unwanted cardiovascular events. 
According to the ESC Guidelines, the following recommen-
dations are [8]: 
1. Healthy adults all ages of 2.5 to 5h a week of moder-
ate physical activity or 1 to 2.5h per week of intense 
physical activity. 
2. Healthy adults who lead a sedentary lifestyle should 
be encouraged to start with a light exercise intensity. 
3. Patients with coronary heart disease (myocardial in-
farction, after aortic coronary bypass or coronary in-
tervention with stable angina pectoris, with stable 
heart failure) need 3 or more times a week moderate 
to intense aerobic exercise for 30 minutes. 
4. Patients with coronary heart disease conducting a 
sedentary lifestyle should begin with light exercise af-
ter CVD risk assessing. 
4.3. Blood Pressure 
 Blood pressure (BP) is commonly defined as persistent 
blood pressure 140/90 mmHg and above, and affects one 
quarter of the adult population [9]. 
 Arterial hypertension (AH) is one of the most important 
preventable factors of premature mortality in the world. AH 
is also the most important independent risk factor of CVD. 
In most developed countries more than 30% of adults suffer 
from AH. Primary prevention should start at the earliest age 
[32]. 
 Arterial hypertension is a risk factor of CVD, but also 
mortality from coronary illness or stroke [8, 33]. CVD risk 
doubled in every increase in BP: diastolic for 10 mmHg and 
systolic for 20 mmHg [33]. 
Classification of BP and AH according to ESC guidelines 
[14]: 
 Systolic BP 
(mmHg) 
 Diastolic BP 
(mmHg) 
Optimal BP <120 and  <80 
Normal BP 120-129 and / or 80-84 
Highly Normal BP 130-139 and / or 85-89 
1st degree AH 140-159 and / or 90-99 
2nd degree AH 160-179 and / or 100-109 
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3rd degree AH ≥180 and / or ≥110 
Isolated systolic AH ≥140 and <90 
 
 According to the new 2017 American Heart Association 
(AHA) Guidelines for high blood pressure in adults AH and 
BP are classified [34]: 
 Systolic BP 
(mmHg) 
 Diastolic BP 
(mmHg) 
Normal BP <120 and    <80 
Elevated  BP 120-129 and    <80 
AH  Stage 1 130-139 or     80-89 
AH Stage 2 ≥140  ≥90 
 
 In order to prevent AH, it is important to encourage the 
following measures in childhood: reducing salt intake, regu-
lar physical activity and prevent obesity. BP can be reduced 
by changing life habits and pharmacotherapy. 
 Life habits in BP reduction include: 
- Reduced intake of salt in food (<5g/day). 
- Decrease in intake of alcoholic beverages (10-
30g/day). 
- Mediterranean diet type (increased omega 3 fatty acid 
intake). 
- Increased physical activity. 
- Smoking cessation. 
- Body weight regulation. 
 According to the ESC guidelines, the goal is to lower BP 
to 140/90 mmHg or to lower than 140/85 mmHg in diabet-
ics. The beginning of pharmacotherapy will depend on the 
estimated total CVD risk and the degree of AH. In the case 
of CVD already present or the target organs are damaged, 
pharmacotherapy starts immediately and the choice of anti-
hypertensive will depend on the already present disease [8, 
33]. 
 AHA guidelines recommend healthy lifestyle for all. 
They recommend one BP lowering medication for the pa-
tients with AH stage 1 if the 10-year risk for heart disease 
and stroke assessment is >10% or they have CVD, diabetes 
mellitus or chronic kidney disease. For the patients with AH 
stage 2 they recommend immediately two medications of 
different class [34].   
4.4. Eating Habits 
 There is a well-known association between eating habits 
and CVD risk. One of the first clinical studies to prove this 
connection is the study of "Seven Countries Study" [35]. It 
has shown a correlation between poor eating habits (food 
rich in saturated fats) and the onset of ischemic heart disease 
[8]. 
 Healthy nutrition is the basis of CV prevention. Food 
habits affect the level of fat and blood sugar, BP, body 
weight. Healthy nutrition reduces the risk of other chronic 
diseases. It is considered that the Mediterranean type of nu-
trition satisfies all the healthy nutritional recommendations 
[9]. Healthy food must contain [12, 36-40]: 
1. Saturated fatty acids <10% of total daily energy in-
take; replace them with polyunsaturated fatty acids. 
2. Transfat acids should be avoided (they are found in 
the factory processed food) and should be <1% of the 
total energy input. 
3. Salt <5g per day. 
4. 30 to 45 grams of fiber per day (whole grains, fruits, 
vegetables). 
5. 200g of fruit a day (2 to 3 meals per day). 
6. 200g vegetables a day (2-3 servings per day). 
7. Fish at least 2x per week (1 meal a week blue fish). 
8. Alcoholic beverages: 2 glasses a day (20g/day) for 
men and 1 glass per day (10g/day) for women. 
Table 1. Stratification of CVD risk. 
Blood Pressure (mmHg) 
Other risk Factors, Asymp-













or DBP ≥ 110 
No other RF     Low risk  Moderate risk  High risk 
1-2 RF  Low risk  Moderate risk  Moderate to high risk  High risk 
≥3 RF  Low to moderate risk  Moderate to high risk  High risk  High risk 
OD, CKD stage 3 or diabetes  Moderate to high risk  High risk  High risk  High to very high risk 
Symptomatic CVD, CKD stage 
≥4 or diabetes with OD/RFs 
Very high risk  Very high risk  Very high risk  Very high risk 
BP = Blood Pressure; CKD = Chronic Kidney Disease; CV = Cardiovascular; CVD = Cardiovascular Disease; DBP = Diastolic Blood Pressure; HT = Hypertension; OD = Organ 
Damage; RF = Risk Factor; SBP = Systolic Blood Pressure. 
Source: http://eurheartj.oxfordjournals.org/content/ehj/34/28/2159.full.pdf 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 According to the new ESC Guidelines on CVD preven-
tion, a population approach has been introduced according to 
dietary measures, physical activity and smoking. Structural 
measures such as limiting marketing and taxing unhealthy 
food, reducing the price of healthy food and making them 
better labelled to make it easier for consumers to view and 
choose (“consumer-friendly”) are important [9]. Healthy 
lifestyles should be stimulated in the community, schools 
and workplaces [8]. 
 The general recommendations of a healthy diet according 
to ESC recommendations are [9]: 
1. A varied well-balanced diet. 
2. Proper energy intake with regular physical activity 
contributes to good body weight control. 
3. Regularly consume fish. 
4. Eat fruits, vegetables, cereals and whole grain prod-
ucts. 
5. Consume non-fat milk products. 
6. Eat unleavened meat, avoid fried. 
7. Use vegetable oils rich in mono and polyunsatu-
rated fats. 
8. Avoid salty and factory processed foods. 
 Legislative regulations (except, of course, existing) are 
needed to limit trans fat acid and salt in food products. The 
food industry can significantly contribute to salt reduction in 
processed food [8]. 
4.5. Obesity  
 The prevalence of obesity in the world is rising, espe-
cially in industrialized countries. It contributes to a signifi-
cant increase in CVD morbidity. The sedentary lifestyle and 
bad nutrition habits are the cause of obesity. Obesity is asso-
ciated with CVD mortality. There is a linear association of 
body mass index (BMI), obesity and especially abdominal 
thickness with total mortality. The lowest mortality rate in 
BMI ranges from 20 to 25 kg/m2 [12]. 
 The effects of obesity are the following [12]: 
1. Increased insulin resistance. 




5. Disorder of the cardiovascular system (endothelial 
dysfunction, coronary heart disease, heart failure, 
atrial fibrillation, stroke, systolic and diastolic left 
heart failure, increased sympathetic activity). 
 The most important is obesity prevention at the earliest 
age. Education and media influence are important in the pre-
vention of child obesity. Each kindergarten, school, and 
working environment should provide a healthy environment 
and healthy meals. Already in childhood, physical activity 
should be promoted. In schools should be provided mini-
mum 30 minutes and an optimum 60 minutes physical activ-
ity per day. Each person should be moderately physically 
active at least 150 minutes a week or more intense physically 
active 75 minutes a week [8]. 
 The basis of obesity treatment is diet, physical activity, 
lifestyle changes. Often, these measures are unsuccessful in 
long-term treatment. In cases of BMI >40 kg/m2 or BMI >35 
kg/m2 with the presence of comorbidities leading the patients 
into a high risk group, including pharmacotherapy (orlistat) 
or bariatric surgery is recommended, along with changes of  
bad lifestyle habits [8]. 
4.6. Lipids 
 In blood plasma lipids (cholesterol and triglycerides) 
circulate as lipoproteins associated with proteins (apolipo-
proteins). Most of the circulating cholesterol is in the form of 
LDL cholesterol (atherogenic) that is directly associated with 
CVD risk. Hypercholesterolemia is an indicator of increased 
risk. There is a positive association between total LDL cho-
lesterol and CVD [8, 12, 13, 41].  The role of triglyceride-
rich lipoprotein is actively studied. These are chylomicrons 
and very low density lipoproteins (VLDL) that can lead to 
pancreatitis at high concentrations [8, 12, 13]. 
 Disturbed lipid metabolism leads to dyslipidemia, which 
alone or in interaction with other CVD risk factors, leads to 
atherosclerosis and consequently CVD. Dyslipidemia can 
also have genetic predisposition (hereditary dyslipidemia), 
can be an integral part of other diseases (secondary dyslipi-
demia), but are mostly the result of external factors (diet rich 
in saturated fats and carbohydrates, reduced body activity, 
smoking, stress) [4]. 
 There are a number of clinical studies that have proven 
that cholesterol reduction leads to a reduction in coronary 
events [12, 42]. The most significant are the following stud-
ies [12]: 
1) Scandinavian Simvastatin Survival Study (4S) [43]. 
2) Long-term Intervention with Pravastatin in Ischaemic 
Disease (LIPID) [44]. 
3) Cholesterol and Recurrent Events (CARE) [45]. 
4) Heart Protection Study (HPS) [46]. 
5) West of Scotland Coronary Prevention Study (WO-
SCOPS) [47]. 
6) Heart AIR Force Texas Coronary Atherosclerosis 
Protection Study (AFCAPS/TexCAPS) [48]. 
 These studies evaluated cardiac patients with hypercho-
lesterolemia. They have demonstrated a positive effect of 
hypolipemic therapy in the prevention of myocardial infarc-
tion and/or cardiac death [27]. 
 For asymptomatic individuals, the first step is an estimate 
of total CVD risk. Within the scope of CVD risk protocols, 
lipid analysis is recommended [4, 13]: 
- Total Cholesterol (TC). 
- Low Density Lipoprotein (LDL)-Cholesterol (LDL-C). 
- Triglycerides (TG). 
- HDL Cholesterol (HDL-C). 
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- Non HDL cholesterol - alternative risk factors (mixed 
dyslipidemia, diabetes, metabolic syndrome, chronic 
kidney disease). 
- Lipoprotein (A) - high CVD risk and positive family 
history of early CVD. 
- APO B - alterative marker (mixed dyslipidemia, dia-
betes, metabolic syndrome, chronic kidney disease). 
- The ratio APO B/APO A (alternative to the probing). 
- The ratio of non HDL C / HDL C (alternative in prob-
ing). 
 LDL C and TC are closely related to CVD risk. LDL C is 
an indicator to therapy response and its values are monitored 
during treatment. It is recommended that appropriate LDL C 
target values be achieved for each patient category [12, 13]: 
1. Very high CVD risk (CVD, diabetes mellitus type 2 
over 40 years and 1 or more risk factors or target or-
gan damage, diabetes mellitus type 1 with target or-
gan damage, moderate to severe chronic kidney dis-
ease, SCORE >10%) - target LDL C <1.8mmol/l 
and/or >50% LDL C if the target LDL C values can-
not be achieved. 
2. High CVD risk (diabetes mellitus type 2 without other 
risk factors or target organ damage, significantly high 
individual risk factors, SCORE >5% and less than 
10%) - target LDL K <2.5mmol/l. 
3. Moderate CVD risk (SCORE >1% and less than 5%) - 
target LDL C <3.0mmol/l. 
 Hypertriglyceridemia is also a risk factor for the devel-
opment of CVD. It is a significant independent CVD risk 
factor, but in relation to hypercholesterolemia, it is less asso-
ciated with CVD [12, 48]. Possible causes of hypertriglyc-
eridemia include obesity, non-insulin-dependent diabetes 
mellitus (NIDDM), alcohol consumption, simple carbohy-
drate-rich diets, chronic kidney disease, hypothyroidism, 
pregnancy, autoimmune diseases, drugs (corticosteroids, 
estrogens, tamoxifen, beta blockers, thiazides, isotretinoin, 
cyclosporine, antiretroviral drugs, psychotropic drugs), but 
also genetic predisposition [4]. 
5. THERAPY OF DYSLIPIDEMIA 
5.1. Hypercholesterolemia 
 General strategies for treatment [4]: 
- Assess the total CVD risk. 
- Involve patients in deciding on risk management. 
- Assess the target value of LDL C for the risk level. 
- Calculate the percentage reduction of the LDL C 
needed to achieve this goal. 
- Select a statin that can achieve this reduction. 
- The dose titration of the drug is required to reach 
the target values of LDL C because the response to 
the treatment of statins is different. 
- Consider introducing a combination of drugs if the 
statins do not reach the LDL target value. 
- Take into account the clinical condition of the pa-
tient, possible drug interactions that the patient is 
taking, statin intolerance. 
 Recommendations for pharmacological treatment of hy-
percholesterolemia [4]: 
- To give statin at the highest dose the patient toler-
ates to achieve the target values of LDL C. 
- In the case of non toleration, administer ionic ex-
changers or nicotinic acid. 
- In the case of non toleration also consider choles-
terol absorption inhibitors, alone or in combination 
with ion exchangers or nicotinic acid. 
- If the target values of LDL C are not reached, con-
sider statin in combination with a cholesterol or 
nicotinic acid absorption inhibitor. 
 Reduction of 1 mmol/l LDL cholesterol leads to 20-25% 
reduction in CV mortality and nonfatal myocardial infarction 
[12, 42]. 
5.2. Hypertriglyceridemia 
 In the case of patients with high total CV risk and TG 
>2.3 mmol/l which cannot be reduced by changing lifestyle, 
the following medications should be given [5]: fibrate, nia-
cin, niacin + laropiprant, omega 3 fatty acid, statin + nico-
tinic acid, statin + fibrate, omega-3 fatty acids combinations. 
Low HDL cholesterol is a factor associated with CVD risk 
[8, 12, 13, 49].  Physical activities and other healthy habits 
increase HDL cholesterol [8]. 
 In mixed dyslipidemia (increased cholesterol and triglyc-
erides) is important to combine therapy. 
 Special groups of dyslipidemia patients who need to re-
ceive statin [40]: 
1. Familial hypercholesterolemia (should receive high 
doses of statin, often in combination with ezetimibe). 
2. Elderly people if they have a proven CVD. 
3. Diabetics (type 1 and microalbuminuria and/or kidney 
disease, type 2 and CVD or chronic renal disease or 
older than 40g with 1 or more CVD risk factors or 
target organ damage, type 2 without additional risk 
factors LDL C should have < 2.6 mmol/l). 
4. Patients with acute coronary syndrome and those pre-
paring for percutaneous coronary intervention. 
5. Severe renal disease. 
6. Peripheral arterial disease. 
7. Primary stroke prevention if a patient with high or 
very high risk and secondary stroke prevention. 
6. DIABETES MELLITUS 
 In 2011, 52 million Europeans aged 20-79 were suffering 
from type 2 diabetes mellitus (T2DM). Until 2030, 64 mil-
lion people in Europe will suffer from T2DM. This is a wor-
rying fact because most diabetics die for CVD [6]. 
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 Diabetes is classified according to the World Health Or-
ganization and the American Diabetes Society on: diabetes 
mellitus type 1 (T1DM), diabetes mellitus type 2 (T2DM), 
"other specific types" DM and gestational DM [6]. 
 According to the ESC guidelines [12] there are diagnos-
tic criteria set by the World Health Organization (WHO) and 
those designated by the American Diabetes Association 
(ADA) in diagnosing diabetes, glucose intolerance and glu-
cose maturation disorder: 
 Diabetes mellitus: HbA1c ≥6.5% (WHO, ADA), GUK 
starving ≥7.0mmol / l (WHO, ADA), glucose after 2h of a 
meal ≥11 mmol/l (WHO, ADA);  
 Glucose intolerance (GI): GUK starving<7mmol/l 
(WHO, ADA), glucose after 2h of the meal ≥7.8 - 
<11.1mmol/l (WHO) and 7.8-11mmol/l (ADA); 
 Glucose maturation disorder: GUK starving 6.1- 
6.9mmol/l (WHO) and 5.6 -6.9mmol/l (ADA), glucose after 
2h of the meal <7.8mmol/l (WHO), and ADA no states the 
criterion. 
 In GI cases, it is important to modify lifestyle habits 
(regulating body weight, increasing body activity and adopt-
ing healthy eating habits) to prevent DM and CVD from de-
veloping or its progression [6]. 
 People with DM are at high risk and do not evaluate their 
risk with the SCORE table. 
 According to the last European Guidelines for Diabetes 
(ESC/EASD), it is recommended to establish patient centres 
[6]. These centres would support patients in achieving 
healthy living habits and advice on improving their own dis-
ease management and treatment. Such centres would have a 
multidisciplinary approach [6]. 
 The ESC/European Association for the Study of Diabetes 
(EASD) guidelines on diabetes in order to prevent CVD give 
the following recommendations [6, 8]: 
- Target HbA1c should be <7%. 
- Statins therapy. 
- Avoid hypoglycemia, as well as increase body 
weight. 
- In the first line of DM treatment give metformin. 
- Further reduction of HbA1c <6.5% can reduce the 
risk of microvascular events. 
- Target BP <140/85mmHg. 
- Target LDL <2.5mmol/l (in case of very high risk of 
LDL <1.8 mmol/l), target cholesterol <4.5mmol/l. 
- Key recommendations in diabetic treatment [6, 8]: 
- Intensive treatment of hypertriglyceridemia reduces 
the CVD risk. 
- Intensive AH treatment reduces the CVD risk. 
- It is often necessary to include more antihypertensive 
drugs in the therapy to achieve the target BP. 
 Each risky CVD factor in diabetes should be treated ac-
cording to the existing recommendations [6, 8]. 
7. PSYCHOSOCIAL FACTORS 
 Low socioeconomic status, lack of social support, stress, 
depression, anxiety, and type D personality increase the risk 
of high risk for the disease [12, 50-53]. These factors also 
make difficult the treatment of cardiovascular patients, as 
well as the impact on the change of bad habits [8]. 
 The risk factors are the following [8, 52, 53]: 
1) Low socioeconomic status - includes low level of 
education, low financial income, low level of business 
status, poor living environment. It leads to an increase 
in CVD mortality. 
2) Social isolation and low social support - people who 
live isolated from society have an increased risk of 
premature deaths, as well as a weaker prognosis of 
CVD. 
3) Work or family stress - increases the risk of CVD. 
4) Depression - increases the incidence of CVD and ex-
acerbates the prognosis of the disease. 
5) Anxiety - increases the risk of CVD. 
6) D type of distress - those with negative affectivity, so-
cial inhibition - has a poorer prognosis of CVD. 
 The biggest problem in evaluating psychosocial factors is 
the fact that they are more difficult to measure, so it is more 
difficult to define the relationship. 
 Poor psychosocial factors are often associated with 
higher incidence of smoking, poor eating habits, decreased 
physical activity, and consequently greater risk of CVD. 
Such patients are more difficult to accept medical advice and 
treatment. The exact pathophysiological effect of psychoso-
cial factors is still being investigated [8]. 
 Interviews or questionnaires should assess psychosocial 
risk factors [1]. The interview should be done by a doctor. In 
order to remove stress, depression, anxiety, and adopt 
healthy living habits, psychosocial interventions are needed. 
According to the ESC guidelines, the following recommen-
dations are on the management of psychosocial factors [9]: 
- Multimodal behavioural interventions, health educa-
tion, physical activity, psychological therapy when 
needed. 
- In the case of clinical symptoms of depression, anxi-
ety should be applied to psychotherapy and pharma-
cotherapy. 
- Interventions include individual and group counseling 
on psychosocial risk factors and how to cope with the 
disease; Cognitive-behavioural therapy, stress man-
agement programs, meditation, autogenic training, 
yoga, breathing exercises, muscular relaxation. Psy-
chological interventions reduce stress, promote 
healthy habits, and affect CVD prevention and treat-
ment. 
CONCLUSION 
 In our day-to-day cardiology practice, we are concerned 
about the high mortality and morbidity of CVD in the world. 
Nearly 50% of Europe's mortality is waste at CVD. Cardi-
CVD Measurable Risk Factors Current Cardiology Reviews, 2018, Vol. 14, No. 3     161 
ologists and public health need information about patients 
and their lifestyle in order to improve the activities of CVD 
prevention and to make prevention more effective. All health 
care professionals should be involved in CVD prevention, 
and all preventive activities should be started by family phy-
sicians. A family medicine practitioner is the one who needs 
to start, coordinate and permanently monitor his/her patient's 
CVD prevention. Thus regrettably, many patients remain 
undiagnosed, and therefore without adequate therapy. Unfor-
tunately, the first manifestation of CVD is sudden dead at 
those patients. Also, among patients with already established 
CVD, many have not achieved the target values of their risk 
factors. In primary prevention, just because of the omitted 
estimates of the CVD risk and the lack of recognition of 
those patients with high and very high risk, no adequate pre-
ventive measures or therapies are implemented. These pa-
tients are endangered by the development of complications 
of illness or fatal CVD outcomes. 
 In Europe, from 1995 to 2014, 4 clinical studies of EU-
ROSPIRE I-IV (Including the Republic of Croatia) investi-
gated the implementation of the ESC guidelines for CVD 
prevention in practice. They have shown that at the level of 
Europe they do not achieve the target values of risk factors 
in primary and secondary prevention. According to the EU-
ROSPIRE III study, only 36-57% of GPs in Europe comply 
with the CVD prevention guidelines and less than 50% of 
them assess the overall risk of their patients. 
 Today, an insufficient number of doctors in their daily 
practice use the SCORE table to estimate CVD risk (62% do 
not use it, but rely on a subjective assessment). There are 
several reasons: government policies and local community 
polices, lack of time in work with a patient (over-burdening 
physicians, insufficient number of cardiologists), SCORE 
table not implemented through information technology, etc. 
 Individual approach to CVD prevention begins with a 
CVD risk assessment: the higher the risk, the prevention 
measures need to be more intense. Clinicians are important 
to make a quick CVD assessment. It is especially important 
in this assessment to identify patients with an unrecognized 
CVD. It would be ideal for all adults to have an estimated 
risk of CVD. A risk assessment of CVD should be repeated 
every 5 years for persons without proven CVD. In that sense, 
cardiologists in outpatient practice have an important role in 
CVD prevention, and need to be consultants of family medi-
cine practitioners and general internists. 
 Cardiologists should do medical evaluation of cardiovas-
cular patients. In this evaluation, the cardiologist will evalu-
ate the risk of CVD, estimate CVD capacity (non-invasive, 
invasive), echocardiographic and Doppler artery estimation. 
This cardiac treatment provides a detailed evaluation and 
assessment of the risk and disease risk. Although identifying 
CVD risk factors, basic treatment and counseling about 
healthy lifestyle habits should be in the domain of GPs and 
general internists, the cardiologist is a counselor in cases 
where doubts remain about the need for introducing therapy 
with preventative measures or there are various contraindica-
tions and/or complications. The cardiologist is always in-
volved in secondary and tertiary CVD prevention. 
 Successful management of measurable variable risk fac-
tors for cardiovascular disease development will include: 
recognizing individual risk factors, monitoring them, and 
assisting in changes in life-style habits that directly affect the 
defined risk factors of a patient. In addition, those risk fac-
tors that can be expected to be the most successful in pre-
venting cardiovascular disease development, if corrected, 
include: smoking habit, increased body mass, physical 
(in)activity, arterial hypertension, dyslipidemia and diabetes. 
In addition to all the above-mentioned risk factors, it is in-
dispensable to include adequate psychosocial support as fu-
ture stress, misunderstanding and patient inadequacy greatly 
reduce the results of preventive actions. 
 The best will be the prevention of the CVD, which in-
cludes a multidisciplinary team of experts and the entire 
community with the support of governmental and non-
governmental organizations that will contribute to improving 
the lifestyle of individuals and the entire community through 
their activities and legal provisions. 
 All health care professionals, including cardiologists, 
need the simplest and most practicable guidelines for CVD 
prevention in accordance with the national, cultural and so-
cioeconomic aspects of their country of work. 
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